Get started
Author

Elisa Giommoni

Observed names: E Giommoni, E. Giommoni, Giommoni, Elisa
ORCID: 0000-0002-1715-8440
Observed ORCID: 0000-0002-1715-8440
OpenAlex ID: A5064858820
Update on gastric cancer treatments and gene therapies
2019 · Alessio Biagioni, Ileana Skalamera, et al. · Cancer and Metastasis Reviews · 183
HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
2016 · F. Pietrantonio, M. Caporale, et al. · International Journal of Cancer · 156
PDF
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
2017 · Filippo Pietrantonio, Giovanni Fucà, et al. · Clinical Cancer Research · 106
PDF
Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey
2013 · Nicola Silvestris, Francesco Pantano, et al. · PLoS ONE · 67
PDF
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
2021 · Agnese Paderi, Roberta Giorgione, et al. · Cancers · 62
PDF
hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications
2014 · Olivia Crociani, Elena Lastraioli, et al. · Clinical Cancer Research · 55
PDF
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
2015 · Filippo Pietrantonio, Chiara Cremolini, et al. · The Oncologist · 51
hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study
2012 · Elena Lastraioli, Lapo Bencini, et al. · Translational Oncology · 51
PDF
Systemic Sclerosis Association with Malignancy
2022 · Gemma Lepri, Martina Catalano, et al. · Clinical Reviews in Allergy & Immunology · 50
Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey
2014 · Daniele Santini, Francesco Pantano, et al. · PLoS ONE · 50
PDF
Results of the observational prospective RealFLOT study
2021 · Elisa Giommoni, Daniele Lavacchi, et al. · BMC Cancer · 46
PDF
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
2019 · Cindy Neuzillet, Andrea Casadei Gardini, et al. · European Journal of Cancer · 44
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
2023 · Francesco Di Costanzo, Francesco Di Costanzo, et al. · Cancers · 41
PDF
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
2021 · Francesca Salvianti, Stefania Gelmini, et al. · British Journal of Cancer · 41
PDF
Evolving pancreatic cancer treatment: From diagnosis to healthcare management
2021 · Michele Milella, Claudio Bassi, et al. · Critical Reviews in Oncology/Hematology · 37
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
2018 · Maria Di Bartolomeo, Monica Niger, et al. · Targeted Oncology · 37
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
2020 · Nicola Silvestris, Oronzo Brunetti, et al. · Cancers · 34
PDF
Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
2021 · Agnese Paderi, Elisabetta Gambale, et al. · Molecules · 33
PDF
Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
2021 · Elisa Giommoni, Roberta Giorgione, et al. · Immuno · 29
PDF
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
2024 · Giovanni Randon, Sara Lonardi, et al. · The Lancet Oncology · 27
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect
2017 · Lorenzo Antonuzzo, Alice Lunghi, et al. · Current Medicinal Chemistry · 27
PDF
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy
2022 · Enrico Caliman, Sara Fancelli, et al. · Cancer Treatment and Research Communications · 25
PDF
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
2021 · G. Orsi, M. Di Marco, et al. · ESMO Open · 24
PDF
A Randomized Phase III Study Evaluating the Continuation of Bevacizumab (BV) Beyond Progression in Metastatic Colorectal Cancer (MCRC) Patients (PTS) Who Received BV as Part of First-Line Treatment: Results of the Bebyp Trial by the Gruppo Oncologico Nord Ovest (GONO)
2012 · G. Masi, F. Loupakis, et al. · Annals of Oncology · 24
Regorafenib Also Can Cause Osteonecrosis of the Jaw
2016 · Lorenzo Antonuzzo, Alice Lunghi, et al. · JNCI Journal of the National Cancer Institute · 23
PDF
Works count: 130
Citation count: 1,600
H-index: 24
I10-index: 39
Year
Topic
Type